hrp0082p1-d3-163 | Growth (2) | ESPE2014
Hart Gili
, Zadik Zvi
, Kradziu Klaudziya
, Zelinska Nataliya
, Malievsky Oleg
, Iotova Violeta
, Skorodok Julia
, Koren Ronit
, Amitzi Leanne
, Fima Eyal
Background: GH replacement therapy currently requires daily injections, which may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) is being developed for once-weekly administration in GH deficient (GHD) children. In the present study the longer term pharmacokinetics (PK) and pharmacodynamics (PD) profile of MOD-4023 in GHD naïve children was assessed.Objective and hypotheses: To assess the long acting prope...